Striatal glutamatergic hyperactivity in Parkinson's disease

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Glutamatergic hyperactivity in the nucleus striatum is implicated in Parkinson's disease (PD) progression.
• Synaptic dysfunctions, particularly glutamate transmission overactivity, are key in early PD stages.
• Abnormalities in spiny projection neuron excitability are observed in PD models.

Purpose of the Study:

• To review evidence linking glutamatergic overactivity to striatal alterations in PD.
• To explore how L-Dopa therapy exacerbates glutamatergic changes, leading to L-Dopa-induced dyskinesias (LIDs).
• To update on pharmacological strategies targeting pre- and postsynaptic glutamatergic systems.

Main Methods:

• Review of preclinical PD models.
• Analysis of clinical studies in PD patients.
• Examination of synaptic and neurotransmitter system alterations.

Main Results:

• Glutamatergic overactivity is a critical mechanism in various PD-associated striatal alterations.
• L-Dopa therapy can lead to complex synaptopathies involving multiple neurotransmitter systems.
• Persistent modifications contribute to the generation of LIDs.

Conclusions:

• Striatal glutamatergic transmission plays a key role in early PD.
• Modulating glutamatergic systems presents a therapeutic avenue for PD and LIDs.
• Understanding these mechanisms is crucial for developing effective PD treatments.